ClinicalTrials.gg
CompletedNCT07754357ICBN/ESPUpdated Oct 28, 2026

Ultrasound-Guided T2 Erector Spinae Plane Block Versus Intercostobrachial Block in AV Fistula Surgery.

An interventional study of Ultrasound Guided Intercostobrachial Nerve Block and Ultrasound Guided Erector Spinae Plane Block at T2 level in ESRD (End Stage Renal Disease), sponsored by Fatma Hatem Mokhtar. Completed at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Fatma Hatem Mokhtar · Not applicable, Interventional, and Treatment

How we know

Updated Oct 28, 2026Now CompletedStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Renal Insufficiency, Chronic with a site in Egypt — 23 open to participants now, 28 under way, 4 of them phase 3. Renal Insufficiency, Chronic · Egypt.

Enrollment
8th of 44
110 · median 64
Started
2026
with 8 others
No phase
23 of 64
5 open now
Registered
63rd of 64
by date

Among the 64 studies in Renal Insufficiency, Chronic with a site in Egypt, this one is the 8th largest by enrollment of the 44 interventional ones that give a count, is one of 9 that started in 2026, is one of 23 with no phase, and was the 63rd registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

23 of the 64 studies in Renal Insufficiency, Chronic with a site in Egypt are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Renal Insufficiency, Chronic with a site in Egypt, or all of them as a file.
02

Study summary

This study aims to determine whether ultrasound guided ESP block at 2nd thoracic vertebrae is non inferior to ultrasound guided ICBN block as adjunct to supraclavicular brachial plexus block in achieving complete sensory blockade of the medial upper arm during AVF superficialization

Read the detailed description

Arteriovenous fistula (AVF) superficialization is an essential procedure for patients with end-stage renal disease . The supraclavicular brachial plexus block is commonly used for upper extremity surgeries .Because the ICBN originates from the T2 nerve root below the C5-T1 nerve roots comprising the brachial plexus, brachial plexus blocks are ideally supplemented with an ICBN infiltration block for medial upper arm coverage.The ICBB requires precise ultrasound guidance to target the ICBN, which is small and variably located, making it technically challenging and time-intensive.

ESP block at T2 level can provide broad coverage, ease of Performance, superficial injection and requiring less technical expertise compared to the ICBB .

The patients are randomly allocated into 2 groups :

  1. Erector spinae plane block group (Group ESP): will receive 10 ml of 0.5% bupivacaine injected into the erector spinae plane at T2 level under ultrasound guidance.
  2. Intercostobrachial block group (Group ICBB): will receive 10 ml of 0.5% bupivacaine injected around intercostobrachial nerve under ultrasound guidance. • Standard Supraclavicular Brachial plexus Block will be performed for all patients using 20 ml of 0.5% bupivacaine under ultrasound guidance.
03

Conditions studied

  • ESRD (End Stage Renal Disease)

Keywords

  • AVF superficialization
  • Intercostobrachial block
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Adults scheduled for upper extremity surgeries under regional anesthesia.

      • Age: 18-65 years.
      • (ASA) III.
      • (BMI) \< 35 kg/m².

Exclusion criteria

Exclusion Criteria:

  • •Allergy to local anesthetics.

    • Coagulopathy or infection at injection sites.
    • Pre-existing neuropathy or significant psychiatric disorders.
    • Pregnant or lactating women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Active comparator
    Ultrasound Guided Intercostobrachial Nerve Block

    1. Position: patient supine with arm abducted. 2. Ultrasound setup: High frequency probe positioned at upper axillary region. 3. Technique: Needle will be advanced into subcutaneous tissue, in-plane to target intercostobrachial nerve near axillary artery. 4. Drug: 10 ml of 0.5% bupivacaine.

    Procedure: Ultrasound Guided Intercostobrachial Nerve Block

  • Active comparator
    Ultrasound Guided Erector Spinae Plane Block at T2 level

    1. Position: patient sitting or in lateral decubitus. 2. Ultrasound setup: High frequency linear transducer will be placed in a parasagittal 2-3 cm lateral to spinous process at T2 level, erector spinae muscles will be identified superficial to the tip of T2 transverse process, patient's skin anesthetized with 3 ml of 2 % lidocaine subcutaneously, the tip of the 22- gauge 80-mm block needle (Sonoplex, Pajunk Medical, Geisingen, Germany) needle will be placed into the facial plane on the deep (anterior) aspect of erector spinae muscle. location of needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process then 10 ml of 0.5% bupivacaine will be injected into the facial plane that will be confirmed by visible hydrodissection .

    Procedure: Ultrasound Guided Erector Spinae Plane Block at T2 level

Interventions

  • ProcedureUltrasound Guided Intercostobrachial Nerve Block

    1. Position: patient supine with arm abducted. 2. Ultrasound setup: High frequency probe positioned at upper axillary region. 3. Technique: Needle will be advanced into subcutaneous tissue, in-plane to target intercostobrachial nerve near axillary artery. 4. Drug: 10 ml of 0.5% bupivacaine.

    Also known as: ICBB

  • ProcedureUltrasound Guided Erector Spinae Plane Block at T2 level

    1. Position: patient sitting or in lateral decubitus. 2. Ultrasound setup: High frequency linear transducer will be placed in a parasagittal 2-3 cm lateral to spinous process at T2 level, erector spinae muscles will be identified superficial to the tip of T2 transverse process, patient's skin anesthetized with 3 ml of 2 % lidocaine subcutaneously, the tip of the 22- gauge 80-mm block needle(Sonoplex, Pajunk Medical, Geisingen, Germany) needle will be placed into the facial plane on the deep (anterior) aspect of erector spinae muscle. location of needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process then 10 ml of 0.5% bupivacaine will be injected into the facial plane that will be confirmed by visible hydrodissection .

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving complete sensory blockade within 30 minutes without conversion to general anesthesia, irrespective of rescue sedation.

    Complete sensory blockade was assessed 30 minutes after completion of the block procedure. Success was defined as achievement of adequate sensory blockade without conversion to general anesthesia, irrespective of rescue sedation. The outcome was recorded as the number and proportion of participants meeting all success criteria in each treatment group.

    Time frame: 30 minutes after completion of the block procedure

Secondary outcomes

  1. Time to achieve complete sensory blockade.

    Time, in minutes, from completion of block placement to achievement of complete sensory blockade, as assessed by the study's sensory-testing procedure.

    Time frame: From completion of block placement until complete sensory blockade is achieved, assessed up to 30 minutes.

  2. Patient's satisfaction (assessed using Likert scale).

    Patient satisfaction assessed using the 5-point Likert scale and the EVAN-LR perioperative satisfaction questionnaire, as specified in the study protocol. The scoring range, interpretation of higher scores, and whether both measures were analyzed separately should be explicitly stated.

    Time frame: At 24 hours; the postoperative assessment.

  3. Total opioid consumption in 24 hours

    Total opioid consumption in 24 hours postoperative in mg /kg

    Time frame: in the first 24 hours

  4. The visual analog scale(VAS)

    measure a patient pain intensty ,commonly used interpretation is 0:no pain,1-3 :mild pain.4-6:moderate pain,7-10 :sever pain

    Time frame: in the first 12 hours

  5. the proportion of participants achieving complete sensory blockade within 30 minutes, without discomfort requiring rescue sedation and without conversion to general anesthesia.

    the proportion of participants achieving complete sensory blockade within 30 minutes, without discomfort requiring rescue sedation and without conversion to general anesthesia.

    Time frame: 30 minutes after completion of the block procedure

07

Study locations

1 site
  • Aswan university hospital
    Aswān, Egypt
08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2026 to primary completion in Oct 2026, 2 months.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's 2 months is below that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

Primary completion moved twice since we started tracking on Sep 25, 2026: Dec 2026 → Oct 2026, last on Oct 28, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Dec 2026 → Oct 2026, last on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Aug 10, 2026
StartActual
Jul 29, 2026
Primary completionActual
Oct 23, 2026was Dec 2026
CompletionActual
Oct 24, 2026was Dec 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Oct 16, 2026
Start date
Jul 21, 2026→Jul 29, 2026
Oct 28, 2026
Primary completion
Dec 15, 2026→Oct 23, 2026
moved 2 times, Oct 16, 2026 – Oct 28, 2026
Study completion
Dec 20, 2026→Oct 24, 2026
moved 2 times, Oct 16, 2026 – Oct 28, 2026
Primary outcomes
Revised in 2 updates
What changed on Oct 16, 2026
  • ChangedBefore Proportion of patients achieving complete sensory blockade during AVF superficializationNow Proportion of Participants Achieving Complete Sensory Blockade Without Discomfort, Sedation, or Conversion to General AnesthesiaTime frame: baseline then at 15,30,60,120 minutes intraoperative assessment for vital signs and sensory blockade → 30 minutes after completion of the block procedure
What changed on Oct 28, 2026
  • EditedProportion of Participants Achieving Complete Sensory Blockade Without Discomfort, Sedation, or Conversioncomplete sensory blockade within 30 minutes without conversion to General Anesthesiageneral anesthesia, irrespective of rescue sedation.Time frame: 30 minutes after completion of the block procedure
across 2 updates, Oct 16, 2026 – Oct 28, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 16, 2026
  • Time frameTime to achieve complete sensory blockade.Time for complete sensory blockade in minutes within 30 minutes → From completion of block placement until complete sensory blockade is achieved, assessed up to 30 minutes.
  • Time framePatient's satisfaction (assessed using Likert scale).At the first 24 hours → At 24 hours; the postoperative assessment.
  • DescriptionPatient's satisfaction (assessed using Likert scale).: how it is measured was reworded
  • DescriptionTime to achieve complete sensory blockade.: how it is measured was reworded
What changed on Oct 28, 2026
  • Addedthe proportion of participants achieving complete sensory blockade within 30 minutes, without discomfort requiring rescue sedation and without conversion to general anesthesia.Time frame: 30 minutes after completion of the block procedure
across 2 updates, Oct 16, 2026 – Oct 28, 2026
Show all 2 updates
  1. Oct 28, 2026
    Start date Jul 21, 2026→Jul 29, 2026
    Primary completion Oct 12, 2026→Oct 23, 2026
    Study completion Oct 12, 2026→Oct 24, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProportion of Participants Achieving Complete Sensory Blockade Without Discomfort, Sedation, or Conversioncomplete sensory blockade within 30 minutes without conversion to General Anesthesiageneral anesthesia, irrespective of rescue sedation.Time frame: 30 minutes after completion of the block procedure
    Secondary outcomes 1 added
    What changed in the outcomes
    • Addedthe proportion of participants achieving complete sensory blockade within 30 minutes, without discomfort requiring rescue sedation and without conversion to general anesthesia.Time frame: 30 minutes after completion of the block procedure
  2. Oct 16, 2026
    Enrolling by invitation→Completed
    Primary completion Dec 15, 2026→Oct 12, 2026 (now actual)
    Study completion Dec 20, 2026→Oct 12, 2026 (now actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Proportion of patients achieving complete sensory blockade during AVF superficializationNow Proportion of Participants Achieving Complete Sensory Blockade Without Discomfort, Sedation, or Conversion to General AnesthesiaTime frame: baseline then at 15,30,60,120 minutes intraoperative assessment for vital signs and sensory blockade → 30 minutes after completion of the block procedure
    Secondary outcomes 2 time frame changed, 2 description edited
    What changed in the outcomes
    • Time frameTime to achieve complete sensory blockade.Time for complete sensory blockade in minutes within 30 minutes → From completion of block placement until complete sensory blockade is achieved, assessed up to 30 minutes.
    • Time framePatient's satisfaction (assessed using Likert scale).At the first 24 hours → At 24 hours; the postoperative assessment.
    • DescriptionPatient's satisfaction (assessed using Likert scale).: how it is measured was reworded
    • DescriptionTime to achieve complete sensory blockade.: how it is measured was reworded

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07754357
Lead sponsor
Fatma Hatem Mokhtar
Collaborators
Aswan University Hospital
Responsible party
Fatma Hatem Mokhtar (Resident doctor of anesthesia,ICU&pain management, Aswan University Hospital) — Sponsor-investigator
First posted
Aug 10, 2026
Start date
Jul 29, 2026
Primary completion
Oct 23, 2026
Completion
Oct 24, 2026
Last update
Oct 28, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion